Selective JAK3 Inhibitor Compounds for Autoimmune Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical agents are inadequate for effectively inhibiting Janus Kinase-3 (JAK3) activity and treating associated diseases such as autoimmune disorders, allergic reactions, and skin disorders, necessitating the development of new and more specific inhibitors.
Innovation Solution
Development of selective JAK3 inhibitor compounds, including specific chemical formulas and their pharmaceutically acceptable salts, which are highly selective for JAK3 over other kinases, demonstrating potential in treating JAK3-associated diseases by modulating JAK3 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmaceutical agents are used, then JAK3 inhibition is achieved, but selectivity over other kinases is insufficient leading to off-target effects
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups (R1-R6) at particular positions on the core heterocyclic structure. These localized chemical modifications create specific interactions with JAK3's binding pocket while avoiding interactions with other kinases, thereby achieving high selectivity without compromising JAK3 inhibition effectiveness
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, positions, and configurations on the core structure. By optimizing these chemical parameters, the compounds achieve enhanced JAK3 binding affinity and selectivity, resolving the contradiction between effective inhibition and off-target effects
2Adaptability or versatility
If broad-spectrum kinase inhibitors are used, then multiple kinase activities are inhibited, but specificity for JAK3 is reduced causing side effects
Solution Approach 1:
The patent extracts the specific JAK3-binding features from broad-spectrum kinase inhibitors by designing a core heterocyclic structure with selective substituent patterns. This extraction approach retains the ability to inhibit kinase activity while removing the non-selective properties that cause side effects, achieving JAK3-specific inhibition
Solution Approach 2:
The patent uses the core heterocyclic structure as an intermediary that mediates selective interaction with JAK3. This intermediary structure with specific substituents acts as a bridge between the desired JAK3 inhibition and the avoidance of other kinase interactions, thereby preventing side effects while maintaining therapeutic efficacy
Data Source
AI summary
The present disclosure relates to methods of modulating (for example, inhibiting) activity of JAK3, comprising contacting the JAK3 with a compound of Formula I or pharmaceutically acceptable salt thereof, wherein constituent members are provided hereinwith. The present disclosure further provides novel compounds and compositions as well as their methods of preparation and use. The disclosed JAK3 inhibitors may be used in the treatment of JAK3-associated diseases including, for example, inflammatory and autoimmune disorders.